Gonadorelin vs Octreotide
Overview
Gonadorelin and Octreotide are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Gonadorelin and Octreotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Gonadorelin | Octreotide | |
|---|---|---|
| Category | Hormonal | Hormonal |
| Regulatory status (US) | Research use only | FDA approved |
| Typical dosage | 100 mcg | 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) |
| Frequency | as prescribed | Every 4 weeks (LAR); two to four times daily (immediate-release) |
| Reported benefits | Fertility support, hormone restoration, reproductive health | Reduction of growth hormone and IGF-1 in acromegaly, suppression of carcinoid flushing and diarrhea, control of VIPoma-associated watery diarrhea, antiproliferative effect on low-grade neuroendocrine tumors, reduction of urinary 5-HIAA biomarkers |
| Reported side effects | Headache, nausea possible | Gallstones and biliary sludge, diarrhea, nausea, abdominal discomfort, sinus bradycardia, hyperglycemia, hypoglycemia, hypothyroidism, steatorrhea, injection-site pain |
Key differences
Primary use. Gonadorelin is categorised under Hormonal, while Octreotide falls under Hormonal. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Gonadorelin: not FDA-approved; treated as a research compound. Octreotide: FDA-approved.
Dosing. Gonadorelin is typically dosed at 100 mcg (as prescribed). Octreotide is typically dosed at 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) (Every 4 weeks (LAR); two to four times daily (immediate-release)).
Can you stack them?
Some protocols combine peptides, but stacking Gonadorelin and Octreotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Gonadorelin and Octreotide?
- Gonadorelin and Octreotide are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status. Gonadorelin is not FDA-approved; generally classified as a research compound, whereas Octreotide is FDA-approved for one or more indications.
- What is Gonadorelin used for?
- GnRH for fertility.
- What is Octreotide used for?
- FDA-approved somatostatin analog for acromegaly, carcinoid syndrome, and VIPomas since 1988.
- Can you take Gonadorelin and Octreotide together?
- Some users combine peptides within a single protocol, but stacking Gonadorelin and Octreotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Gonadorelin or Octreotide FDA-approved?
- Gonadorelin is not FDA-approved; generally classified as a research compound. Octreotide is FDA-approved for one or more indications.
Read the full articles
- Gonadorelin — full monograph: mechanism, research, dosing & references
- Octreotide — full monograph: mechanism, research, dosing & references